98%
921
2 minutes
20
Early identification of high-risk metabolic dysfunction-associated steatohepatitis (MASH) can offer patients access to novel therapeutic options and potentially decrease the risk of progression to cirrhosis. This study aimed to develop an explainable machine learning model for high-risk MASH prediction and compare its performance with well-established biomarkers. Data were derived from the National Health and Nutrition Examination Surveys (NHANES) 2017-March 2020, which included a total of 5281 adults with valid elastography measurements. We used a FAST score ≥ 0.35, calculated using liver stiffness measurement and controlled attenuation parameter values and aspartate aminotransferase levels, to identify individuals with high-risk MASH. We developed an ensemble-based machine learning XGBoost model to detect high-risk MASH and explored the model's interpretability using an explainable artificial intelligence SHAP method. The prevalence of high-risk MASH was 6.9%. Our XGBoost model achieved a high level of sensitivity (0.82), specificity (0.91), accuracy (0.90), and AUC (0.95) for identifying high-risk MASH. Our model demonstrated a superior ability to predict high-risk MASH vs. FIB-4, APRI, BARD, and MASLD fibrosis scores (AUC of 0.95 vs. 0.50, 0.50, 0.49 and 0.50, respectively). To explain the high performance of our model, we found that the top 5 predictors of high-risk MASH were ALT, GGT, platelet count, waist circumference, and age. We used an explainable ML approach to develop a clinically applicable model that outperforms commonly used clinical risk indices and could increase the identification of high-risk MASH patients in resource-limited settings.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11016071 | PMC |
http://dx.doi.org/10.1038/s41598-024-59183-4 | DOI Listing |
Saudi J Gastroenterol
September 2025
Department of Medicine, Liver Disease Research Centre, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
The reclassification of nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) marks a significant shift in understanding liver disease, particularly in Saudi Arabia, where metabolic disorders are highly prevalent. This study aimed to develop expert consensus recommendations for early detection, specialist referral, and management of MASLD/metabolic dysfunction-associated steatohepatitis (MASH) in Saudi Arabia. A modified Delphi process was used to establish consensus among an expert panel of 15 multidisciplinary specialists, including hepatologists, endocrinologists, gastroenterologists, and primary care physicians.
View Article and Find Full Text PDFEur Radiol
August 2025
Department of Radiology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Objectives: To develop and evaluate a novel multi-parameter MRI-based model (EFT1) for identifying high-risk metabolic dysfunction-associated steatohepatitis (MASH) to improve diagnostic accuracy and efficiency.
Materials And Methods: A prospective study included 118 patients (55 male; 48 ± 13 years) with hepatic steatosis and metabolic risk factors. Among these, 80 patients were classified as having high-risk MASH.
Clin Transl Med
August 2025
Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, with high rates of post-resection recurrence posing significant clinical challenges. Early recurrence is largely driven by aggressive tumor biology, while late recurrence reflects de novo carcinogenesis in a cirrhotic liver. Traditional clinical and pathological predictors are insufficient for accurately identifying high-risk patients.
View Article and Find Full Text PDFPostgrad Med
August 2025
eDivision of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, Florida, USA.
Can Liver J
December 2024
Joint Department of Medical Imaging, University Health Network, Toronto, ON, Canada.
Background: Significant fibrosis (≥stage 2) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) is considered a high risk for morbidity and mortality. The magnetic resonance elastography (MRE) and FIB-4 (MEFIB) Index (MRE ≥ 3.3 kPa and FIB-4 ≥ 1.
View Article and Find Full Text PDF